阅读说明：本技术 一种便于鉴定抗药物治疗的生物标志物 (Biomarker convenient for identifying anti-drug therapy ) 是由 毛彬臣 薛佳 钱武斌 于 2021-01-26 设计创作，主要内容包括：本发明公开了一种便于鉴定抗药物治疗的生物标志物,涉及生物标志物技术领域,该便于鉴定抗药物治疗的生物标志物原料由牛蒡子8-14份、人参7-11份、地榆11-13份、半夏9-11份、黄芪10-15份、牛膝8-10份、甘草12-14份、雷公藤13-15份和水菖蒲10-12份组成。本发明采用中药滤液和鉴定剂的结合,方便对患者进行药物抗药性进行鉴定的同时,并配合中药滤液中的分子成分对癌细胞中的有害分子进行治疗的作用,在对使用者进行检验的同时能够对其起到一定的治疗作用,避免了在鉴定的同时减少患者的疼痛,使用多种中药组合得到的滤液,具备一定的解毒抗癌的作用,而通过siRNA、凝血酶溶液、环磷酰胺和抗体组合设置,可以抑制癌细胞的繁殖,并且能够增强人体T细胞的免疫系统。(The invention discloses a biomarker convenient for identifying anti-drug therapy, and relates to the technical field of biomarkers, wherein the raw materials of the biomarker convenient for identifying anti-drug therapy comprise 8-14 parts of burdock, 7-11 parts of ginseng, 11-13 parts of sanguisorba officinalis, 9-11 parts of pinellia ternata, 10-15 parts of astragalus membranaceus, 8-10 parts of achyranthes bidentata, 12-14 parts of liquorice, 13-15 parts of tripterygium wilfordii and 10-12 parts of acorus calamus. The invention adopts the combination of the traditional Chinese medicine filtrate and the identification agent, is convenient for identifying the drug resistance of a patient, and is matched with the effect of treating harmful molecules in cancer cells by molecular components in the traditional Chinese medicine filtrate, can play a certain treatment role while checking a user, avoids the pain of the patient while identifying, has a certain detoxifying and anticancer effect by using the filtrate obtained by combining a plurality of traditional Chinese medicines, can inhibit the propagation of the cancer cells and can enhance the immune system of T cells of a human body by combining siRNA, thrombin solution, cyclophosphamide and antibodies.)

1. A biomarker that facilitates identification of anti-drug therapy, characterized by: the biomarker raw materials convenient for identifying the anti-drug therapy consist of 8-14 parts of burdock, 7-11 parts of ginseng, 11-13 parts of garden burnet, 9-11 parts of pinellia ternate, 10-15 parts of astragalus membranaceus, 8-10 parts of achyranthes bidentata, 12-14 parts of liquorice, 13-15 parts of tripterygium wilfordii and 10-12 parts of acorus calamus, and the preparation method of the biomarker convenient for identifying the anti-drug therapy comprises the following steps:

the method comprises the following steps: taking materials, weighing the raw materials according to the weight of the raw materials, and respectively taking 12g of burdock, 9g of ginseng, 12g of garden burnet, 10g of pinellia ternate, 13g of astragalus membranaceus, 9g of achyranthes bidentata, 13g of liquorice, 14g of tripterygium wilfordii and 11g of acorus calamus;

step two: soaking, namely adding water which is 3-4 times of the total weight of the medicinal materials into the medicinal material raw materials weighed in the step one, and cleaning and soaking for 90-120 min;

step three: cooking, namely cooking the medicinal materials soaked in the step two for 2-3 times for 90-120h to obtain filtrate;

step four: mixing the filtrates, extracting the above filtrates, and adding identification agent to obtain biomarker.

2. A biomarker to facilitate identification of anti-drug therapy according to claim 1, wherein: the biomarker convenient for identifying the anti-drug therapy is prepared from the following raw materials in parts by weight: 9.3-11.6 parts of burdock, 7.2-9.6 parts of ginseng, 10.7-12.3 parts of garden burnet, 8.5-10.8 parts of pinellia ternate, 9.3-14.2 parts of astragalus, 8.5-9.5 parts of achyranthes bidentata, 11.6-13.7 parts of liquorice, 12.3-15.6 parts of tripterygium wilfordii and 8.6-13.4 parts of acorus calamus.

3. A biomarker to facilitate identification of anti-drug therapy according to claim 1, wherein: according to the fourth step, the identification agent is prepared by taking siRNA, thrombin solution, cyclophosphamide and antibody as main components and adding fibrinogen solution and mixing, and the weight ratio of the cost is as follows:

siRNA 16.73%，

21.83 percent of thrombin solution,

9.33 percent of cyclophosphamide,

1.27 percent of the antibody,

the rest is added with fibrinogen solution.

4. A biomarker to facilitate identification of anti-drug therapy according to claim 3, wherein: the preparation method of the identifier in the fourth step comprises the following steps:

s1, mixing the siRNA serving as a basic raw material with cyclophosphamide, reducing the mixture, and uniformly mixing the reduced mixture with a fibrinogen solution to obtain a preparation solution;

s2, stirring, mixing and adding the preparation solution obtained in the step S1 and thrombin solution at the temperature of 32-36 ℃ to obtain an identifier;

s3, testing the identified PH value in the step S2, and sterilizing.

5. A biomarker to facilitate identification of anti-drug therapy according to claim 3, wherein: the volume ratio of the thrombin solution to the fibrinogen drug solution is 1.217: 2.434.

Technical Field

The invention relates to the technical field of biomarkers, in particular to a biomarker convenient for identifying anti-drug therapy.

Background

At present, cancer is one of the main diseases which seriously affect human health and threaten human life at present, and the cancer, cardiovascular and cerebrovascular diseases and accidents together form three causes of death in all countries in the world at present. Therefore, the world health organization and the government health departments of all countries take cancer as a first task, cancer cells are the source of cancer, and different from normal cells, the cancer cells have the characteristics of unlimited proliferation, transformation and easy metastasis, can be unlimited proliferation and damage normal cell tissues, and the world methods for treating the cancer mainly comprise three methods: firstly, a surgical resection method is adopted to resect pathological tissues and prevent cancer cells from diffusing; secondly, chemotherapy or radiotherapy is adopted to kill cancer cells; thirdly, the medicine treatment.

Biomarkers are typically biochemical indicators of a general physiological or pathological or therapeutic process that can be objectively measured and evaluated, and the progress of the biological process in which the body is currently located can be determined. Examination of a disease-specific biomarker may be helpful in the identification, early diagnosis and prevention of disease, and monitoring of disease treatment. The search and discovery of valuable biomarkers has become an important hotspot of current research.

At present, when an identification drug is used for marking cells, although the marking of the cells can be achieved, the effect of inhibiting cancer cells cannot be achieved, the immune system of a human body cannot be improved, the good treatment effect on the human body cannot be achieved, the applicability of the biomarker convenient for identifying the anti-drug treatment is poor, and therefore structural innovation is needed to solve specific problems.

Disclosure of Invention

The technical problem to be solved by the invention is to provide a biomarker convenient for identifying anti-drug therapy, wherein one purpose is to solve the problem that only a single pair of biomarkers can not treat harmful molecules in cells when the biomarkers are carried out on the cells; another purpose is to solve the problem that the immune system of human T cells cannot be improved, so as to achieve the effect of improving the activity of human cells when carrying out the biomarkers, and be beneficial to improving the immunity of the human body.

In order to solve the technical problems, the technical scheme adopted by the invention is as follows:

a biomarker convenient for identifying anti-drug therapy is prepared from 8-14 parts of burdock, 7-11 parts of ginseng, 11-13 parts of sanguisorba officinalis, 9-11 parts of pinellia ternate, 10-15 parts of astragalus membranaceus, 8-10 parts of achyranthes bidentata, 12-14 parts of liquorice, 13-15 parts of tripterygium wilfordii and 10-12 parts of acorus calamus, and the preparation method of the biomarker convenient for identifying anti-drug therapy comprises the following steps:

the method comprises the following steps: taking materials, weighing the raw materials according to the weight of the raw materials, and respectively taking 12g of burdock, 9g of ginseng, 12g of garden burnet, 10g of pinellia ternate, 13g of astragalus membranaceus, 9g of achyranthes bidentata, 13g of liquorice, 14g of tripterygium wilfordii and 11g of acorus calamus;

step two: soaking, namely adding water which is 3-4 times of the total weight of the medicinal materials into the medicinal material raw materials weighed in the step one, and cleaning and soaking for 90-120 min;

step three: cooking, namely cooking the medicinal materials soaked in the step two for 2-3 times for 90-120h to obtain filtrate;

step four: mixing the filtrates, extracting the above filtrates, and adding identification agent to obtain biomarker.

Further, the biomarker convenient for identifying the anti-drug therapy is prepared from the following raw materials in parts by weight: 9.3-11.6 parts of burdock, 7.2-9.6 parts of ginseng, 10.7-12.3 parts of garden burnet, 8.5-10.8 parts of pinellia ternate, 9.3-14.2 parts of astragalus, 8.5-9.5 parts of achyranthes bidentata, 11.6-13.7 parts of liquorice, 12.3-15.6 parts of tripterygium wilfordii and 8.6-13.4 parts of acorus calamus.

Further, according to the fourth step, the identification agent is prepared by taking siRNA, thrombin solution, cyclophosphamide and antibody as main components, adding fibrinogen solution and mixing, wherein the weight ratio of the cost is as follows:

siRNA 16.73%，

21.83 percent of thrombin solution,

9.33 percent of cyclophosphamide,

1.27 percent of the antibody,

the rest is added with fibrinogen solution.

Further, the preparation method of the identifier in the fourth step comprises the following steps:

s1, mixing the siRNA serving as a basic raw material with cyclophosphamide, reducing the mixture, and uniformly mixing the reduced mixture with a fibrinogen solution to obtain a preparation solution;

s2, stirring, mixing and adding the preparation solution obtained in the step S1 and thrombin solution at the temperature of 32-36 ℃ to obtain an identifier;

s3, testing the identified PH value in the step S2, and sterilizing.

Further, the volume ratio of the thrombin solution to the fibrinogen drug solution is 1.217: 2.434.

Due to the adoption of the technical scheme, the invention has the technical progress that:

the invention provides a biomarker convenient for identifying anti-drug therapy, which adopts the combination of traditional Chinese medicine filtrate and an identifying agent to conveniently identify drug resistance of patients, and aiming at the problem that the traditional Chinese medicine has certain components with better curative effect on cancer cells, the molecular components in the prepared traditional Chinese medicine filtrate have the effect of treating harmful molecules in the cancer cells, can play a certain role in treatment while checking the user, avoids the pain of the patient while identifying, the filtrate obtained by combining a plurality of traditional Chinese medicines has certain detoxifying and anticancer effects, and the combination of siRNA, thrombin solution, cyclophosphamide and antibody can inhibit the propagation of cancer cells and enhance the immune system of human T cells, thereby being beneficial to improving the activity of human cells and playing a certain positive role in eliminating cancer cells in human bodies.

Detailed Description

The present invention will be described in further detail with reference to the following examples:

the invention provides a biomarker convenient for identifying anti-drug therapy, which is prepared from 8-14 parts of burdock, 7-11 parts of ginseng, 11-13 parts of garden burnet, 9-11 parts of pinellia ternate, 10-15 parts of astragalus, 8-10 parts of achyranthes root, 12-14 parts of liquorice, 13-15 parts of tripterygium wilfordii and 10-12 parts of acorus calamus, and the preparation method of the biomarker convenient for identifying anti-drug therapy comprises the following steps:

the method comprises the following steps: taking materials, weighing the raw materials according to the weight of the raw materials, and respectively taking 12g of burdock, 9g of ginseng, 12g of garden burnet, 10g of pinellia ternate, 13g of astragalus membranaceus, 9g of achyranthes bidentata, 13g of liquorice, 14g of tripterygium wilfordii and 11g of acorus calamus;

step two: soaking, namely adding water which is 3-4 times of the total weight of the medicinal materials into the medicinal material raw materials weighed in the step one, and cleaning and soaking for 90-120 min;

step three: cooking, namely cooking the medicinal materials soaked in the step two for 2-3 times for 90-120h to obtain filtrate;

step four: mixing the filtrates, extracting the above filtrates, and adding identification agent to obtain biomarker.

Preferably, the biomarker convenient for identifying the anti-drug therapy is prepared from the following raw materials in parts by weight: 9.3-11.6 parts of burdock, 7.2-9.6 parts of ginseng, 10.7-12.3 parts of garden burnet, 8.5-10.8 parts of pinellia ternate, 9.3-14.2 parts of astragalus, 8.5-9.5 parts of achyranthes bidentata, 11.6-13.7 parts of liquorice, 12.3-15.6 parts of tripterygium wilfordii and 8.6-13.4 parts of acorus calamus.

According to the fourth step, the identification agent is prepared by taking siRNA, thrombin solution, cyclophosphamide and antibody as main components and adding fibrinogen solution and mixing, and the weight ratio of the cost is as follows:

siRNA 16.73%，

21.83 percent of thrombin solution,

9.33 percent of cyclophosphamide,

1.27 percent of the antibody,

the rest is added with fibrinogen solution.

The preparation method of the identifier in the fourth step comprises the following steps:

s1, mixing the siRNA serving as a basic raw material with cyclophosphamide, reducing the mixture, and uniformly mixing the reduced mixture with a fibrinogen solution to obtain a preparation solution;

s2, stirring, mixing and adding the preparation solution obtained in the step S1 and thrombin solution at the temperature of 32-36 ℃ to obtain an identifier;

s3, testing the identified PH value in the step S2, and sterilizing.

The volume ratio of the thrombin solution to the fibrinogen drug solution was 1.217: 2.434.

The invention has the beneficial effects that: by the delicate design and the combination of the traditional Chinese medicine filtrate and the identification agent, the drug resistance of the patient can be conveniently identified, and aiming at the problem that the traditional Chinese medicine has certain components with better curative effect on cancer cells, the molecular components in the prepared traditional Chinese medicine filtrate have the effect of treating harmful molecules in the cancer cells, can play a certain role in treatment while checking the user, avoids the pain of the patient while identifying, the filtrate obtained by combining a plurality of traditional Chinese medicines has certain detoxifying and anticancer effects, and the combination of siRNA, thrombin solution, cyclophosphamide and antibody can inhibit the propagation of cancer cells and enhance the immune system of human T cells, thereby being beneficial to improving the activity of human cells and playing a certain positive role in eliminating cancer cells in human bodies.

Animal toxicity testing of the biomarkers of the invention:

short-term toxicity test: taking 4 adult mice as two groups, wherein the weight of the adult mice is 100-.

Long-term toxicity test: taking adult mice 4 which are divided into two groups, wherein the weight is 220-240kg, and dividing the two groups into two groups, namely injecting the biomarker convenient for identifying the anti-drug therapy into the two groups of mice, wherein one group is an overdose experimental group, the other group is a normal dose experimental group, the overdose experimental group is injected with 6-7 times of the human dose, the normal dose experimental group is injected with 4-5 times of the human dose (calculated according to the weight proportion), the injecting is continuously performed for 15-20 days respectively, and the immune cell activity in the mice is detected every other week, and the result shows that the animal survival state is good, no toxic reaction and pathological change are seen, and the drug is proved to have no toxic or side effect.

Clinical efficacy of the biomarkers of the invention:

by administering the above biomarkers for easy identification of anti-drug therapies to a plurality of groups of users 'cells, respectively, it was observed that after administering the above biomarkers to the users continuously for 72 hours, the cancer cells in the users' bodies were significantly reduced and the immune systems of the users were significantly enhanced.

The present invention has been described in general terms in the foregoing, but it will be apparent to those skilled in the art that modifications and improvements can be made thereto based on the present invention. Therefore, modifications or improvements are within the scope of the invention without departing from the spirit of the inventive concept.